SPOREs
Breast
Cores
TISSUE and PATHOLOGY
Specific Aim: To establish a tissue and pathology resource that will be available to SPORE investigators that is linked to clinical data via a secure data management system.
Goal: To acquire and link clinical data collected through the Clinical Research Information System (CRIS) with prospectively collected tissue and blood samples.
Expertise: This Core provides pathological evaluation of specimens, microdissection, RNA amplification, RNA and DNA isolation from microdissected and macrodissected tissue samples, quantitative real-time PCR using RNA derived from frozen, and FFPE samples and immunohistochemistry
MGH Tumor Bank: Collects, stores and processes breast core biopsy samples in conjunction with SPORE neoadjuvant therapeutic trials. In addition to frozen tissue samples, the MGH Tumor Bank provides access to all formalin-fixed paraffin-embedded breast cancer, normal breast and benign breast disease tissue. The Bank also provides SPORE researchers’ access to amplified RNA derived from malignant cells of the various stages of breast cancer progression.
BWH Tumor Bank: Collects breast tumor and matched normal tissues, normal breast tissues from reduction mammoplasties, and metastatic breast cancer specimens. These samples can be provided to investigators as required as fresh tissue for cell sorting or tissue culture experiments, as frozen tissue or frozen sections, or as extracted DNA, RNA, or protein. The Bank collects, stores, and processes breast core biopsy samples in conjunction with SPORE neo-adjuvant trials.
SPORE Serum and Blood Repository (SSBR): As of June 2007, 7,917 patients have been consented and have given blood samples from which serum or plasma and whole blood have been collected and stored. In addition, 3,697 consented high-risk patients have provided blood samples.
Clinical Trials: Collection of specimens from breast cancer patients enrolled in clinical treatment studies. As of June 2007, 31 clinical trials have used this Core for sample collection and storage.
Sourcing Tissue
To order tissue, please complete this Breast Tissue Request Form.
To order blood, please complete this Blood Bank Request Form.
Key Personnel
Andrea Richardson, MD, PhD – BWH
Stuart J. Schnitt, MD – BIDMC
Dennis Sgroi, MD – MGH
Penelope Miron, PhD – DFCI
Recent Publications
Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, and Freedman ML: Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007, 121: 2661-2667
DeYoung MP, Horak P, Sofer A, Sgroi D, and Ellisen LW: Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 2008, 22: 239-251
Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, and Winer EP: Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007, 13: 1198-1207
Leong CO, Vidnovic N, DeYoung MP, Sgroi D, and Ellisen LW: The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007, 117: 1370-1380
Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, and Sgroi D: A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clin Cancer Res 2008, 14: 2601-2608
Wang Z, Dahiya S, Provencher H, Muir B, Carney E, Coser K, Shioda T, Ma XJ, and Sgroi DC: The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clin Cancer Res 2007, 13: 6327-6334
Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, Van't Veer LJ, and Ramaswamy S: Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort. Clin Cancer Res 2008, 14: 2988-2993
Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A, Violette S, Nikolskaya T, Nikolsky Y, Bauerlein EL, Hahn WC, Gelman RS, Allred C, Bissell MJ, Schnitt S, Polyak K. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008 May;13(5):394-406.
Overholtzer M, Mailleux AA, Mouneimne G, Normand G, Schnitt SJ, King RW, Cibas ES, Brugge JS. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell. 2007 Nov 30;131(5):966-79.
Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, Huntsman D. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet. 2007 Nov;44(11):726-31.
Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 Mar;11(3):259-73.
Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR, Andzelm MM, Strominger JL, Brown M, Hemler ME. CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res. 2008 May 1;68(9):3204-13.
Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat. 2008 Mar;108(2):191-201.
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007 Oct 4;449(7162):557-63.
Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell. 2007 Aug;12(2):160-70.
Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15;129(6):1065-79.
Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, Kutok JL, Hartwell K, Richardson AL, Weinberg RA. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10069-74.
